Literature DB >> 33926377

Risk factors for secondary hemophagocytic lymphohistiocytosis in severe coronavirus disease 2019 adult patients.

Mei Meng1,2, Limin Chen1, Sheng Zhang1, Xuan Dong3, Wenzhe Li1,2, Ranran Li1, Yunxin Deng1,2, Tao Wang1,2, Yan Xu1,2, Jiao Liu1,2, Yanxia Huang1,2, Yizhu Chen1,2, Sisi Huang1, Zhenliang Wen1,2, Lidi Zhang1,2, Hangxiang Du1,2, Yongan Liu1,2, Djillali Annane4, Jieming Qu5,6, Dechang Chen7.   

Abstract

BACKGROUND: Secondary hemophagocytic lymphohistiocytosis (sHLH) is a life-threatening hyperinflammatory event and a fatal complication of viral infections. Whether sHLH may also be observed in patients with a cytokine storm induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is still uncertain. We aimed to determine the incidence of sHLH in severe COVID-19 patients and evaluate the underlying risk factors.
METHOD: Four hundred fifteen severe COVID-19 adult patients were retrospectively assessed for hemophagocytosis score (HScore). A subset of 7 patients were unable to be conclusively scored due to insufficient patient data.
RESULTS: In 408 patients, 41 (10.04%) had an HScore ≥169 and were characterized as "suspected sHLH positive". Compared with patients below a HScore threshold of 98, the suspected sHLH positive group had higher D-dimer, total bilirubin, alanine aminotransferase, aspartate aminotransferase, blood urea nitrogen, serum creatinine, triglycerides, ferritin, interleukin-6, C-reactive protein, procalcitonin, lactate dehydrogenase, creatine kinase isoenzyme, troponin, Sequential Organ Failure Assessment (SOFA) score, while leukocyte, hemoglobin, platelets, lymphocyte, fibrinogen, pre-albumin, albumin levels were significantly lower (all P < 0.05). Multivariable logistic regression revealed that high ferritin (>1922.58 ng/mL), low platelets (<101 × 109/L) and high triglycerides (>2.28 mmol/L) were independent risk factors for suspected sHLH in COVID-19 patients. Importantly, COVID-19 patients that were suspected sHLH positive had significantly more multi-organ failure. Additionally, a high HScore (>98) was an independent predictor for mortality in COVID-19.
CONCLUSIONS: HScore should be measured as a prognostic biomarker in COVID-19 patients. In particular, it is important that HScore is assessed in patients with high ferritin, triglycerides and low platelets to improve the detection of suspected sHLH.

Entities:  

Keywords:  COVID-19; Cytokine storm; Ferritin; HScore; Platelet; Secondary Hemophagocytic Lymphohistiocytosis; Triglycerides

Year:  2021        PMID: 33926377     DOI: 10.1186/s12879-021-06094-8

Source DB:  PubMed          Journal:  BMC Infect Dis        ISSN: 1471-2334            Impact factor:   3.090


  21 in total

1.  The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).

Authors:  Mervyn Singer; Clifford S Deutschman; Christopher Warren Seymour; Manu Shankar-Hari; Djillali Annane; Michael Bauer; Rinaldo Bellomo; Gordon R Bernard; Jean-Daniel Chiche; Craig M Coopersmith; Richard S Hotchkiss; Mitchell M Levy; John C Marshall; Greg S Martin; Steven M Opal; Gordon D Rubenfeld; Tom van der Poll; Jean-Louis Vincent; Derek C Angus
Journal:  JAMA       Date:  2016-02-23       Impact factor: 56.272

2.  Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome.

Authors:  Laurence Fardet; Lionel Galicier; Olivier Lambotte; Christophe Marzac; Cedric Aumont; Doumit Chahwan; Paul Coppo; Gilles Hejblum
Journal:  Arthritis Rheumatol       Date:  2014-09       Impact factor: 10.995

Review 3.  The liver in congestive heart failure: a review.

Authors:  G D Dunn; P Hayes; K J Breen; S Schenker
Journal:  Am J Med Sci       Date:  1973-03       Impact factor: 2.378

Review 4.  Hemophagocytic Lymphohistiocytosis.

Authors:  Hanny Al-Samkari; Nancy Berliner
Journal:  Annu Rev Pathol       Date:  2017-09-13       Impact factor: 23.472

Review 5.  Adult haemophagocytic syndrome.

Authors:  Manuel Ramos-Casals; Pilar Brito-Zerón; Armando López-Guillermo; Munther A Khamashta; Xavier Bosch
Journal:  Lancet       Date:  2013-11-27       Impact factor: 79.321

6.  Pulmonary Involvement in Patients With Hemophagocytic Lymphohistiocytosis.

Authors:  Amélie Seguin; Lionel Galicier; David Boutboul; Virginie Lemiale; Elie Azoulay
Journal:  Chest       Date:  2016-01-13       Impact factor: 9.410

7.  Acute respiratory distress syndrome: the Berlin Definition.

Authors:  V Marco Ranieri; Gordon D Rubenfeld; B Taylor Thompson; Niall D Ferguson; Ellen Caldwell; Eddy Fan; Luigi Camporota; Arthur S Slutsky
Journal:  JAMA       Date:  2012-06-20       Impact factor: 56.272

8.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors:  Chaolin Huang; Yeming Wang; Xingwang Li; Lili Ren; Jianping Zhao; Yi Hu; Li Zhang; Guohui Fan; Jiuyang Xu; Xiaoying Gu; Zhenshun Cheng; Ting Yu; Jiaan Xia; Yuan Wei; Wenjuan Wu; Xuelei Xie; Wen Yin; Hui Li; Min Liu; Yan Xiao; Hong Gao; Li Guo; Jungang Xie; Guangfa Wang; Rongmeng Jiang; Zhancheng Gao; Qi Jin; Jianwei Wang; Bin Cao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

Review 9.  COVID-19 gone bad: A new character in the spectrum of the hyperferritinemic syndrome?

Authors:  Serena Colafrancesco; Cristiano Alessandri; Fabrizio Conti; Roberta Priori
Journal:  Autoimmun Rev       Date:  2020-05-05       Impact factor: 9.754

10.  COVID-19: consider cytokine storm syndromes and immunosuppression.

Authors:  Puja Mehta; Daniel F McAuley; Michael Brown; Emilie Sanchez; Rachel S Tattersall; Jessica J Manson
Journal:  Lancet       Date:  2020-03-16       Impact factor: 79.321

View more
  4 in total

Review 1.  Hemophagocytic lymphohistiocytosis diagnosed by bone marrow trephine biopsy in living post-COVID-19 patients: case report and mini-review.

Authors:  Maria Ioannou; Konstantina Zacharouli; Sotirios G Doukas; Michael D Diamantidis; Vaya Tsangari; Konstantinos Karakousis; George K Koukoulis; Dimitra P Vageli
Journal:  J Mol Histol       Date:  2022-06-14       Impact factor: 3.156

2.  COVID-19 associated EBV reactivation and effects of ganciclovir treatment.

Authors:  Mei Meng; Sheng Zhang; Xuan Dong; Wenqing Sun; Yunfeng Deng; Wenzhe Li; Ranran Li; Djillali Annane; Zhixiong Wu; Dechang Chen
Journal:  Immun Inflamm Dis       Date:  2022-04

3.  Case Report: Secondary Hemophagocytic Lymphohistiocytosis (sHLH) and Candida auris Fungemia in Post-acute COVID-19 Syndrome: A Clinical Challenge.

Authors:  Sachin Gautam; Gaurav Sharma; Sumeet Singla; Sandeep Garg
Journal:  Front Med (Lausanne)       Date:  2022-06-17

4.  COVID-19-A Trigger Factor for Severe Immune-Mediated Thrombocytopenia in Active Rheumatoid Arthritis.

Authors:  Anca Bobircă; Florin Bobircă; Ioan Ancuța; Anca Florescu; Mihai Bojincă; Alice Muscă; Dan Nicolae Florescu; Lucian Mihai Florescu; Romina Marina Sima; Alesandra Florescu; Anca Emanuela Mușetescu
Journal:  Life (Basel)       Date:  2022-01-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.